Hormone Research in Paediatrics
Original Paper
Twenty-Four-Hour Serum Growth Hormone, Insulin, C-Peptide and Blood Glucose Profiles and Serum Insulin-Like Growth Factor-l Concentrations in Women with Polycystic OvariesPrelević G.M.a · Wurzburger M.I.a · Balint-Perić L.a · Ginsburg J.baDepartment of Endocrinology, ‘Zvezdara’ University Medical Centre, Belgrade University School of Medicine, Belgrade, Yugoslavia; bDepartment of Endocrinology, Royal Free Hospital and School of Medicine, London, UK
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: November 19, 1991
Accepted: April 01, 1992
Published online: December 03, 2008
Issue release date: 1992
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)
For additional information: https://www.karger.com/HRP
Abstract
Raised insulin levels are now recognized as a characteristic feature of women with polycystic ovaries (PCO), and hyperinsulinism has been shown to stimulate androgen production in such women. We have, however, recently shown that hyperinsulinaemia is present only in the obese subjects with PCO in whom insulin concentrations correlate with those of luteinizing hormone. We therefore studied 24-hour blood profiles of growth hormone (GH) and insulinlike growth factor-I (IGF-I) in obese and non-obese women with PCO, for comparison with their levels of insulin, C-peptide and other hormones, such as androgens which are known to be disturbed in PCO. Mean 24-hour GH levels were higher overall in PCO than in control subjects, although the difference was not significant. When, however, a separate analysis was made in obese as compared with non-obese PCO patients, GH concentrations were significantly higher in the non-obese group than in the obese (p = 0.0005). There was a significant negative correlation between body mass index and mean 24-hour GH concentrations (r = -0.641; p = 0.0006). IGF-I concentrations were however similar in the PCO group overall and in controls, as well as in the obese and non-obese PCO patients. The 24-hour blood glucose profile pattern was significantly different in PCO women from controls (p = 0.009), with absence of post-prandial peaks in blood glucose concentrations. These changes were most marked in the non-obese PCO group, who also had significantly lower blood glucose levels than either controls or obese PCO subjects. Significantly higher 24-hour C-peptide and insulin concentrations were found in the obese PCO group compared with controls and the non-obese PCO group. The absence of typical post-prandial increases in insulin and C-peptide concentrations was also evident in the non-obese PCO subjects. There was a significant negative correlation between the 24-hour C-peptide and mean 24-hour GH values (r = – 0.629; p = 0.0212) in the PCO group. Our finding of higher GH concentrations in non-obese PCO patients together with lower blood glucose and normal IGF-I concentrations could theoretically be explained in terms of altered IGF-binding protein concentration, which in turn would influence the biological potency of IGF-I and regulation of GH secretion. These findings would also support the concept that part of the disturbance in patients with PCO lies between that of insulin and IGF-I binding protein.
© 1992 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Received: November 19, 1991
Accepted: April 01, 1992
Published online: December 03, 2008
Issue release date: 1992
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)
For additional information: https://www.karger.com/HRP
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
